Quick answer: Men’s health spans one of the most rapidly changing landscapes in functional medicine — testosterone levels in American men have declined 1% per year since 1987 (Travison et al. 2007 Journal of Clinical Endocrinology & Metabolism), with the average 60-year-old man today having testosterone levels equivalent to a 70-80 year old in 1987. Simultaneously, benign prostatic hyperplasia affects 50% of men over 50, prostate cancer is the second most common male cancer, and erectile dysfunction has become a clinical cardiovascular risk marker. Functional medicine identifies the root causes behind these trends and implements evidence-based interventions that conventional urology rarely addresses.
The Testosterone Decline Epidemic: Causes and Clinical Impact
The Travison 2007 JCEM study (n=1,532 men, 3 cohorts) documented a population-level testosterone decline of approximately 1% per year independent of aging — meaning each successive birth cohort has lower testosterone at the same age than the previous cohort. This cannot be explained by individual aging; it reflects generational environmental and lifestyle changes.
Contributing factors to population testosterone decline:
Endocrine disrupting chemicals (EDCs): Phthalates (plasticizers in food packaging, personal care products, medical devices) inhibit Leydig cell testosterone synthesis — Swan 2005 demonstrated significant inverse correlation between urinary phthalate metabolites and testosterone in male infants. Bisphenol A (BPA) and bisphenol S (BPS) act as estrogen receptor agonists, disrupting the HPG axis feedback and reducing LH-stimulated testosterone production. Organochlorine pesticides (DDT metabolites) retain estrogenic activity decades after banning. PFAS compounds interfere with testosterone synthesis pathways. Feng 2015 systematic review confirmed consistent inverse associations between multiple EDC exposures and testosterone levels in adult men.
Obesity and insulin resistance: Adipose tissue contains aromatase — the enzyme that converts testosterone to estradiol. Visceral obesity creates a self-amplifying cycle: elevated estradiol suppresses GnRH/LH (reducing testosterone synthesis), reduced testosterone favors fat accumulation, which increases aromatase activity further. A 10-point increase in BMI is associated with approximately 15% reduction in testosterone. Insulin resistance additionally impairs Leydig cell function via IGF-1 signaling disruption.
Sleep disruption: Testosterone production is primarily nocturnal — pulsatile LH release during slow-wave sleep drives Leydig cell testosterone synthesis. Leproult 2011 Sleep (n=10, RCT) demonstrated that restricting sleep to 5 hours for 8 days reduced testosterone by 10-15% — equivalent to 10 years of aging. Sleep apnea — highly prevalent in overweight men — further reduces testosterone through both sleep architecture disruption and nocturnal hypoxemia.
Chronic stress and elevated cortisol: Cortisol competitively inhibits testosterone at the androgen receptor level and directly suppresses Leydig cell function via glucocorticoid receptors. The HPG axis and HPA axis are reciprocally inhibitory — chronic stress reduces testosterone as a direct physiological trade-off (Tsai 2011 Psychoneuroendocrinology).
Nutritional deficiencies: Zinc is an essential cofactor for testosterone synthesis and LH receptor function — Prasad 1996 demonstrated significantly higher testosterone in zinc-supplemented marginally deficient men. Vitamin D acts as a steroid hormone with a receptor on Leydig cells; Pilz 2011 Hormone and Metabolic Research RCT demonstrated 65.1 IU/mL free testosterone increase with vitamin D supplementation in deficient men. Magnesium correlates with free testosterone — Cinar 2011 demonstrated higher testosterone in magnesium-supplemented exercising men.
Diagnosing Testosterone Deficiency: The Complete Male Hormone Panel
Standard testosterone testing — serum total testosterone alone — frequently mischaracterizes male hormone status:
Total testosterone: Measures all testosterone, including protein-bound (metabolically inactive). Standard labs report “normal” range 300-1000 ng/dL — an enormous range spanning the 5th to 95th percentile of a population including men with frank hypogonadism. Many patients are symptomatic at 300-450 ng/dL. Functional medicine optimal total testosterone: 500-900 ng/dL for men seeking vitality and metabolic health.
Free testosterone: The biologically active fraction (approximately 2-3% of total) not bound to SHBG or albumin. Can be measured directly (equilibrium dialysis — the gold standard) or calculated from total testosterone, SHBG, and albumin. Optimal free testosterone: >15 ng/dL (Bhasin 2010 JCEM consensus). A man with total testosterone of 450 ng/dL and very high SHBG (>60 nmol/L, driven by thyroid disease, liver disease, or estrogen exposure) may have free testosterone of only 8 ng/dL — symptomatic functional hypogonadism with “normal” total testosterone.
SHBG (sex hormone-binding globulin): The primary testosterone-binding protein. SHBG is elevated by: thyroid hormone (hyperthyroidism dramatically elevates SHBG), estrogen (including exogenous sources), aging, insulin sensitivity improvement (paradoxically — reducing free testosterone even while increasing SHBG). SHBG is reduced by: insulin resistance, obesity, hypothyroidism, anabolic steroids, and certain medications. Understanding SHBG explains why total testosterone can be “normal” while free testosterone is low, or vice versa.
LH (luteinizing hormone) and FSH (follicle-stimulating hormone): Essential for distinguishing primary hypogonadism (testicular failure — elevated LH/FSH) from secondary/central hypogonadism (hypothalamic-pituitary failure — low or inappropriately normal LH/FSH). Secondary hypogonadism is most common in functional medicine — driven by obesity, sleep apnea, opioid use, anabolic steroid history, pituitary tumors, and hypothalamic suppression from EDC exposure or chronic illness. Low testosterone with low LH suggests secondary hypogonadism requiring investigation of the HPG axis.
Estradiol (E2): In men, estradiol (target: 20-30 pg/mL) is essential for libido, bone density, cognitive function, and cardiovascular health — not merely a “female hormone.” Estradiol below 15 pg/mL causes bone loss, depressed mood, and reduced libido even with adequate testosterone. Estradiol above 50 pg/mL in men contributes to gynecomastia, water retention, suppressed LH/testosterone, and increased thrombosis risk. Elevated male estradiol is almost always from aromatase excess — driven by obesity, zinc deficiency, alcohol, and certain medications.
Prolactin: Elevated prolactin (>20 ng/mL) suppresses GnRH secretion and is the most common pituitary cause of secondary hypogonadism. Causes: prolactinoma (pituitary tumor — requires MRI), hypothyroidism, dopamine antagonist medications (antipsychotics, metoclopramide), and chronic stress. A prolactin level should be in every male hypogonadism workup.
Natural Testosterone Optimization: Evidence-Based Lifestyle and Nutritional Interventions
Before considering testosterone replacement therapy (TRT), functional medicine systematically addresses modifiable contributors to testosterone decline:
Resistance training: Acute testosterone increase after resistance exercise is well-established (Daly 2010), and chronic resistance training increases basal testosterone levels — particularly compound movements (squat, deadlift, bench press) at moderate-to-high intensity. Kraemer 1998 Medicine & Science in Sports and Exercise demonstrated sustained anabolic hormonal adaptations with progressive resistance training programs.
Weight loss (particularly visceral fat reduction): A 10-15% body weight reduction consistently increases testosterone by 30-50% in obese hypogonadal men — via reduced aromatase activity and improved HPG axis sensitivity. This is the single most powerful intervention for obesity-associated secondary hypogonadism, often restoring testosterone to the normal range without TRT.
Sleep optimization: Achieving 7-8 hours of sleep with adequate slow-wave sleep content (optimized by consistent sleep timing, magnesium glycinate, and sleep apnea treatment) can increase testosterone by 15-20% — comparable to pharmacological interventions in sleep-deprived men.
Zinc and vitamin D optimization: Ensure zinc 25-40 mg/day in deficient men, vitamin D 50-80 ng/mL serum level. These are prerequisites before any other intervention — deficiency in either significantly limits testosterone synthesis capacity.
Ashwagandha (KSM-66): Wankhede 2015 JISSN RCT (n=57): ashwagandha extract 300mg BID for 8 weeks produced 15% testosterone increase and 17.3% DHEA-S increase vs placebo in resistance-trained men. Langade 2019 Medicine RCT demonstrated KSM-66 reduced cortisol by 27.9% — addressing the cortisol-testosterone inverse relationship. The testosterone-supporting effects of ashwagandha appear mediated via cortisol reduction and LH sensitization.
Shilajit (purified): Biswas 2010 Andrologia (n=35, RCT): purified shilajit 200mg BID for 90 days increased total testosterone by 23.5%, free testosterone by 19.1%, and DHEA-S by 17.3% vs placebo in healthy volunteers aged 45-55. Shilajit contains fulvic acid and dibenzo-alpha-pyrones that appear to stimulate Leydig cell function and mitochondrial energy production in testicular tissue.
Boron: Naghii 2011 Journal of Trace Elements demonstrated 10mg/day boron for 7 days increased free testosterone by 28.3% and reduced estradiol by 39.2% in healthy men — via inhibition of SHBG binding and reduced aromatase activity. Boron also supports bone density, cognitive function, and inflammation reduction.
When to Consider TRT: The Functional Medicine Decision Framework
Testosterone replacement therapy (TRT) is appropriate when: (1) Total testosterone is consistently below 350-400 ng/dL (morning, fasting, duplicate measurements), (2) Symptoms are present (fatigue, reduced libido, erectile dysfunction, sarcopenia, cognitive changes, depression), (3) Secondary causes have been addressed or excluded, and (4) The patient understands the implications for fertility (TRT suppresses spermatogenesis by reducing FSH/LH — men desiring future fertility should consider clomiphene or hCG protocols instead).
Modern TRT delivery options: injectable testosterone cypionate/enanthate (most common — weekly or biweekly injections maintain stable levels), topical gel/cream (daily application, absorption variability, risk of transfer to female partners and children), intranasal testosterone (Natesto — minimal HPG axis suppression, useful for fertility-preserving TRT), subcutaneous pellets (3-6 month duration, convenient but difficult to adjust dose).
Functional medicine TRT monitoring: total and free testosterone, estradiol, hematocrit (polycythemia risk — target <54%), PSA (prostate-specific antigen), liver function, lipid panel. The landmark Testosterone and Cardiovascular Events (TRAVERSE) trial (Lincoff 2023 NEJM, n=5,246 men with hypogonadism and cardiovascular risk): TRT did not increase MACE (major adverse cardiovascular events) but was associated with a higher rate of nonfatal arrhythmia (particularly atrial fibrillation) — important monitoring consideration.
Prostate Health: BPH, Cancer Prevention, and the DHT Connection
Benign prostatic hyperplasia (BPH) — prostate enlargement causing urinary symptoms (urgency, frequency, weak stream, nocturia) — affects 50% of men over 50 and 90% of men over 80. The conventional pharmaceutical approach (alpha-blockers, 5-alpha reductase inhibitors) addresses symptoms but not underlying causes. Functional medicine identifies the metabolic drivers of prostate hyperplasia:
DHT and 5-alpha reductase: Dihydrotestosterone (DHT) — formed from testosterone by 5-alpha reductase enzyme — is the primary androgen driving prostate growth. 5-alpha reductase inhibitors (finasteride, dutasteride) reduce prostate volume by 20-30% and reduce DHT by 65-90%. The functional medicine approach: dietary 5-alpha reductase inhibition via saw palmetto (Permixon) — Cochrane review by Tacklind 2012 (32 RCTs, n=5,666) found saw palmetto extracts equivalent to tamsulosin (alpha-blocker) for urinary symptom improvement; lycopene (cooked tomatoes) reduces 5-alpha reductase activity and reduces PSA in PCa surveillance studies (Kucuk 2001, Proctor 2017); beta-sitosterol — concentrated in pumpkin seeds (1-2 oz daily provides clinically relevant doses) — inhibits 5-alpha reductase and directly reduces DHT-stimulated prostate cell proliferation (Berges 1995 Lancet RCT n=200 demonstrated improved urinary symptoms).
Estrogen-DHT imbalance: Both estrogen and DHT are prostate growth signals — and the ratio matters as much as absolute levels. Elevated estradiol from aromatization (obesity, zinc deficiency, alcohol) combined with elevated DHT creates the most potent prostate hyperplasia stimulus. DIM (diindolylmethane from cruciferous vegetables), zinc, and calcium-D-glucarate support estrogen metabolism and reduce estrogen-driven prostate stimulation.
Insulin resistance and prostate growth: Insulin is a direct prostate growth factor via IGF-1 receptor signaling on prostate cells. Metabolic syndrome and insulin resistance are independent risk factors for both BPH and prostate cancer — controlling insulin through low-glycemic diet and exercise reduces prostate growth signaling substantially.
Prostate cancer prevention — the functional medicine evidence: Selenium (Clark 1996 JAMA SELECT precursor study, SeleMed 2003), vitamin E — the SELECT trial (Lippman 2009 JAMA) was designed to test selenium and vitamin E for prostate cancer prevention; SELECT showed synthetic vitamin E (alpha-tocopherol only, not mixed tocopherols) actually increased prostate cancer risk — an important lesson about the difference between isolated synthetic vitamins and whole-food nutrient complexes. Lycopene — the Harvard Health Professionals Follow-up Study demonstrated 21% reduced prostate cancer risk in the highest lycopene consumers, with cooked tomatoes showing greater protective effect than raw. Green tea (EGCG) — Kurahashi 2008 Cancer Science demonstrated inverse association between green tea consumption and prostate cancer risk in Japanese men; Bettuzzi 2006 Cancer Research RCT showed green tea catechins reduced prostate cancer incidence from 30% to 3% in high-grade PIN patients.
Erectile Dysfunction as a Cardiovascular Biomarker
Erectile dysfunction (ED) is now recognized as a clinical cardiovascular risk marker — specifically, an early warning sign of systemic endothelial dysfunction that precedes symptomatic cardiovascular disease by 2-5 years (Montorsi 2003 European Urology, the “artery size hypothesis”). The penile arteries (1-2mm diameter) develop atherosclerotic dysfunction before the larger coronary arteries (3-4mm diameter) — making ED an early diagnostic window for cardiovascular disease.
Thompson 2005 NEJM demonstrated that men with ED had a 45% increased risk of subsequent cardiovascular events — independent of traditional risk factors. Functional medicine approach to ED: evaluate and treat the cardiovascular risk drivers (ApoB, Lp(a), hsCRP, homocysteine, insulin resistance) alongside the ED itself. A patient presenting with new-onset ED at age 45 should receive a comprehensive cardiovascular risk assessment, not simply a PDE5 inhibitor prescription.
Endothelial function and nitric oxide: Erectile function depends fundamentally on nitric oxide (NO) — cGMP-mediated smooth muscle relaxation in penile vasculature that enables blood flow and engorgement. Endothelial dysfunction (reduced NO bioavailability from oxidative stress, inflammation, and aging) is the primary pathophysiological mechanism of organic ED. Functional interventions targeting NO production: L-citrulline (converted to arginine in the kidney — more efficient than direct arginine supplementation) — Cormio 2011 Urology RCT 1.5g/day improved erectile hardness in mild-to-moderate ED; dietary nitrates from beets and leafy greens (converted to NO via oral bacteria and acidic gastric environment — mouthwash use destroys this conversion pathway); cocoa flavanols (Heiss 2015 demonstrated endothelial function improvement with 450mg cocoa flavanols/day).
Testosterone’s role in ED: Testosterone is permissive for NO synthesis in penile tissue — it upregulates endothelial nitric oxide synthase (eNOS) and phosphodiesterase type 5 (the target of sildenafil/tadalafil). Men with low testosterone have reduced response to PDE5 inhibitors — a significant clinical observation, as combining TRT with PDE5 inhibition in testosterone-deficient men with ED produces synergistic improvement (Buvat 2012 European Urology).
Functional Men’s Health at The Private Practice
Dr. Biernacki’s men’s health evaluation provides what a standard urological or primary care visit cannot: a comprehensive hormonal assessment (complete male hormone panel with free testosterone, SHBG, estradiol, LH, FSH, prolactin), metabolic evaluation (insulin resistance, inflammatory markers, cardiovascular biomarkers), and EDC exposure assessment — combined with evidence-based optimization protocols targeting the root causes of testosterone decline, prostate dysfunction, and erectile dysfunction.
The goal is not simply replacing what has been lost — it is identifying and removing the obstacles to optimal male hormonal function, so that natural production can be maximized and longevity-promoting interventions can take hold. For men who do require TRT, functional medicine optimizes the protocol with appropriate estradiol management, metabolic support, and monitoring. To schedule a comprehensive men’s health evaluation with Dr. Biernacki, call (810) 206-1402 or visit theprivatepractice.co.
Frequently Asked Questions About Functional Men’s Health
Q: Does testosterone therapy cause prostate cancer?
A: The evidence does not support a causal link between TRT and prostate cancer incidence. The “saturation model” (Morgentaler 2009 European Urology) demonstrates that prostate growth is androgen-receptor dependent — once testosterone occupies all androgen receptors (occurring at relatively low testosterone levels), further testosterone increases do not stimulate additional growth. The large TRAVERSE trial (2023, n=5,246) found no increased prostate cancer incidence with TRT. However, TRT is contraindicated in patients with known or suspected prostate cancer. PSA monitoring during TRT is standard — a rapid PSA rise (>0.75 ng/mL/year) warrants urological evaluation regardless of absolute PSA level.
Q: What natural supplements actually raise testosterone?
A: Evidence-based supplements with RCT support: (1) Ashwagandha KSM-66 (300mg BID) — 15% testosterone increase in Wankhede 2015. (2) Shilajit purified (200mg BID) — 23.5% increase in Biswas 2010. (3) Boron (10mg/day) — 28% free testosterone increase, 39% estradiol reduction in Naghii 2011. (4) Zinc (supplementation in deficient men). (5) Vitamin D (supplementation to 50-80 ng/mL in deficient men — Pilz 2011). Supplements with weaker or contradictory evidence: fenugreek, longjack (eurycoma longifolia), D-aspartic acid (mixed results), tribulus terrestris (most studies show no testosterone effect in healthy men).
Q: At what age should men start monitoring testosterone?
A: Functional medicine recommends baseline testosterone assessment at age 35-40 in all men — establishing a personal baseline before the natural decline of late andropause. Men with risk factors (obesity, metabolic syndrome, sleep apnea, high stress, EDC exposure, opioid use) should begin monitoring earlier — age 25-30. The trajectory of testosterone over time is clinically meaningful: a man declining from 750 ng/dL at age 35 to 480 ng/dL at age 45 has lost 37% of his peak testosterone and may be symptomatic, even though both values are technically “within reference range.”
Q: Can erectile dysfunction be reversed without medication?
A: For mild-to-moderate organic ED, functional medicine interventions produce clinically significant improvement: testosterone optimization (when deficient), L-citrulline supplementation, dietary nitrate intake, weight loss and exercise (both directly improve endothelial function), cardiovascular risk reduction (treating the underlying atherosclerotic process), sleep apnea treatment, and reduction of EDC exposure. Esposito 2004 JAMA demonstrated that Mediterranean diet plus exercise produced erectile function improvement in obese men equivalent to PDE5 inhibitor effects. For psychogenic ED, cognitive-behavioral sex therapy is highly effective. Medication-free resolution of ED is achievable for many patients — but requires addressing root causes rather than symptom suppression.